Adenosine Antagonists Show Promise in Clinical Trials for Cancer and COPD
核心洞察
Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases (搜索), oncology (搜索), and cardiovascular disorders (搜索).
Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes.
Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer (搜索), prostate cancer and COPD (搜索).
Adenosine antagonists are emerging as potential therapeutics for a range of diseases, with several companies reporting promising clinical trial data. These compounds work by blocking adenosine receptors (搜索), modulating physiological processes such as sleep regulation, cardiovascular function, and immune response. Recent studies suggest that adenosine antagonists could enhance anti-tumor immune responses and offer new treatment options for conditions like cancer and COPD (搜索).
Advancements in Adenosine Antagonist Development
DelveInsight’s 'Adenosine Antagonists Pipeline Insight 2024' report highlights a robust pipeline with over 10 active players developing more than 12 adenosine antagonists. Key companies such as Arcus Biosciences, Corvus Pharmaceuticals, and iTeos Therapeutics are evaluating new drugs to improve treatment outcomes.
Clinical Trial Highlights
- Corvus Pharmaceuticals: In November 2024, Corvus Pharmaceuticals announced data highlighting the potential of ciforadenant to overcome resistance to anti-PD1 immunotherapy in metastatic castration-resistant prostate cancer.
- iTeos Therapeutics: In October 2024, iTeos Therapeutics presented preclinical and clinical data from inupadenant at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024.
- Palobiofarm: On September 9, 2024, Palobiofarm announced positive top-line results in a Phase II trial of PBF-680 in patients with moderate-to-severe COPD.
- Arcus Biosciences: In June 2024, Gilead Sciences and Arcus Biosciences shared new data from a Phase Ib/II study (ARC-9) evaluating etrumadenant plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy, and bevacizumab in third-line metastatic colorectal cancer.
Adenosine Antagonists in Oncology
In oncology (搜索), adenosine antagonists are being explored for their potential to enhance anti-tumor immune responses. Tumors often elevate extracellular adenosine levels to suppress the activity of T cells and natural killer cells, thereby evading immune surveillance. By blocking adenosine receptors (搜索), particularly A2A and A2B, these antagonists can restore the immune system's ability to recognize and attack cancer cells. This strategy is being investigated in combination with immune checkpoint inhibitors to improve outcomes in cancer immunotherapy.
Pipeline Therapies
Several adenosine antagonists are currently in various stages of clinical development:
- Etrumadenant (Arcus Biosciences): Phase II trials for colorectal cancer, non-small cell lung cancer, pancreatic cancer, and rectal cancer.
- Ciforadenant (Corvus Pharmaceuticals): Phase II trials for renal cell carcinoma.
- Inupadenant (iTeos Therapeutics): Phase II trials for non-small cell lung cancer.
- PORT-6/PORT 7 (Portage Biotech): Phase I/II trials for non-small cell lung cancer, prostate cancer, and renal cell carcinoma.
- PBF-680 (Palobiofarm): Phase II trial for COPD.